Justin Klee (L) and Josh Cohen (Amylyx)
ALS player Amylyx bags $190M as it sets sail on Nasdaq amid choppy waters
ALS drug developer Amylyx got off its IPO on Friday, raising $190 million after pricing its stock at the midrange of the offering and bumping …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
